Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -0.99 is 31% above its 5-year average of -1.43, near the high end of its 5-year range (-3.01–-0.96).
As of the fiscal period ended Tuesday, June 30, 2026. 20.77% above its 12-month average of -1.25.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): -0.99.
DEBT TO EQUITY RATIO
-0.99
DEBT TO EQUITY RATIO AVG TTM
-1.25
DEBT TO EQUITY RATIO AVG 3Y
-1.32
DEBT TO EQUITY RATIO AVG 5Y
-1.43
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+20.77%
CURRENT VS 3Y AVG
+25.03%
CURRENT VS 5Y AVG
+30.86%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.17
median of 337 covered companies
CURRENT VS SECTOR MEDIAN
-683.22%
vs the sector median at left
BridgeBio Pharma, Inc.
Market Cap
$12.95B
Debt to Equity Ratio
-0.99
TTM Avg
-1.25
3Y Avg
-1.32
5Y Avg
-1.43
Market Cap
$12.89B
Debt to Equity Ratio
0.37
TTM Avg
0.39
3Y Avg
0.44
5Y Avg
0.45
Market Cap
$13.19B
Debt to Equity Ratio
0.01
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.00
Market Cap
$12.52B
Debt to Equity Ratio
1.56
TTM Avg
1.78
3Y Avg
2.05
5Y Avg
1.83
Market Cap
$12.17B
Debt to Equity Ratio
1.17
TTM Avg
1.60
3Y Avg
3.59
5Y Avg
3.91
Market Cap
$12.00B
Debt to Equity Ratio
1.09
TTM Avg
1.21
3Y Avg
1.62
5Y Avg
1.75
Market Cap
$14.16B
Debt to Equity Ratio
0.31
TTM Avg
1.29
3Y Avg
0.69
5Y Avg
0.46
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | $12.95B | -0.99 | -1.25 | -1.32 | -1.43 |
| ICON Public Limited Company (ICLR)vs › | $12.89B | 0.37 | 0.39 | 0.44 | 0.45 |
| Corcept Therapeutics Incorporated (CORT)vs › | $13.19B | 0.01 | 0.01 | 0.01 | 0.00 |
| Baxter International Inc. (BAX)vs › | $12.52B | 1.56 | 1.78 | 2.05 | 1.83 |
| Penumbra, Inc. (PEN)vs › | $12.49B | 0.14 | 0.17 | 0.20 | 0.18 |
| BrightSpring Health Services, Inc. Common Stock (BTSG)vs › | $12.17B | 1.17 | 1.60 | 3.59 | 3.91 |
| Encompass Health Corporation (EHC)vs › | $12.00B | 1.09 | 1.21 | 1.62 | 1.75 |
| Ascendis Pharma A/S (ASND)vs › | $14.16B | 0.31 | 1.29 | 0.69 | 0.46 |
| DaVita Inc. (DVA)vs › | $11.47B | N/A | 55.08 | 35.65 | 25.99 |
| Bio-Techne Corporation (TECH)vs › | $11.36B | 0.14 | 0.18 | 0.20 | 0.21 |
Debt/Equity
-0.99
Current Ratio
1.23
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | -0.99 |
| 2026-03-31 | -1.49 |
| 2025-12-31 | -1.31 |
| 2025-09-30 | -0.96 |
| 2025-06-30 | -1.50 |
| 2025-03-31 | -1.13 |
| 2024-12-31 | -1.18 |
| 2024-09-30 | -1.41 |
| 2024-06-30 | -1.58 |
| 2024-03-31 | -1.65 |
| 2023-12-31 | -1.28 |
| 2023-09-30 | -1.44 |
| 2023-06-30 | -1.27 |
| 2023-03-31 | -1.41 |
| 2022-12-31 | -1.37 |
| 2022-09-30 | -1.51 |
| 2022-06-30 | -1.67 |
| 2022-03-31 | -1.66 |
| 2021-12-31 | -1.98 |
| 2021-09-30 | -1.88 |
| 2021-06-30 | -3.01 |
| 2021-03-31 | -3.50 |
| 2020-12-31 | 8.56 |
| 2020-09-30 | 2.95 |
| 2020-06-30 | 1.80 |
| 2020-03-31 | 1.24 |
| 2019-12-31 | 0.22 |
| 2019-09-30 | 0.16 |
| 2019-06-30 | -0.24 |
| 2019-03-31 | 0.22 |
| 2018-12-31 | -0.33 |
| 2018-09-30 | 0.00 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
